Linxis Biopharmaceuticals

Executive Summary

LinXis Biopharmaceuticals is a clinical-stage Dutch biotech pioneering targeted therapeutics and diagnostics for fibrotic diseases via its proprietary Fibrobody® platform. The platform engineers protein vectors that selectively bind activated myofibroblasts—the primary drivers of fibrosis—enabling precise delivery of drug payloads or imaging tracers. This approach aims to overcome limitations of current antifibrotic therapies, which lack specificity and cause systemic side effects. LinXis is advancing a pipeline of Fibrobody-drug conjugates across multiple fibrosis indications, with its lead candidate in Phase 2/3 trials. The company's technology has potential applications in organ fibrosis (liver, lung, kidney) and rare fibrotic conditions, offering a first-in-class modality for a large unmet medical need. LinXis has generated preclinical proof-of-concept data demonstrating enhanced target engagement and reduced toxicity compared to standard of care. Its lead program is advancing through late-stage clinical development, positioning the company for potential regulatory milestones. The Fibrobody platform also supports diagnostic imaging tracers for non-invasive fibrosis monitoring, which could accelerate drug development and improve patient management. With a strong intellectual property estate and a focus on fibrosis—a multi-billion dollar market with limited effective treatments—LinXis represents a compelling investment opportunity in targeted biologic therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 interim efficacy data readout for lead Fibrobody-drug conjugate in liver fibrosis60% success
• H1 2027Potential partnership or licensing deal for Fibrobody platform in lung or kidney fibrosis40% success
• Q2 2027IND submission for new Fibrobody-based imaging tracer for non-invasive fibrosis assessment75% success